AtriCure (ATRC) | Stock Overview & Key Data
AtriCure Performance Comparison
Stock Range
Today's Range
Low: $35.16
High: $36.44
on August 8, 2025
52 Week Range
Low: $20.20
High: $43.11
on August 8, 2024
on January 29, 2025
All-Time High: $89.18 on November 1, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.8B
EPS
-0.77
P/E Ratio (TTM)
-37.85
Forward P/E
-57.97
P/B Ratio
3.91
PEG Ratio
-57.97
Div. Yield
N/A
ROE
-7.85%
Beta
1.621
Debt to Equity
16.63
Financial Highlights
Profitability
Gross Margin
74.54%
Operating Margin
-4.55%
Profit Margin
-7.27%
Returns and Earnings
Return on Assets (TTM)
-3.53%
Return on Equity (TTM)
-7.85%
EBITDA
$-14.1M
Net Income (TTM)
$-36.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$10.23
Quarterly Revenue Growth (YoY)
17.10%
Quarterly Earnings Growth (YoY)
17.09%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| AtriCure ATRC | 1.82B Small-cap | 2.62% | 11.63% | 13.25% | -15.97% | 16.15% | 68.91% | -32.05% | -12.16% |
| Intuitive Surgical ISRG | 169.94B Large-cap | -2.70% | -10.85% | -12.65% | -21.09% | -10.30% | 1.43% | 97.21% | 106.02% |
| Becton, Dickinson BDX | 53.31B Large-cap | 9.71% | 10.81% | 15.21% | -15.70% | -14.57% | -17.97% | -26.61% | -23.17% |
| Lemaitre Vascular LMAT | 2.11B Mid-cap | 13.87% | 9.97% | 13.23% | -6.26% | 0.89% | 10.17% | 68.46% | 225.16% |
| Anbio Biotechnology NNNN | 1.87B Small-cap | 19.30% | 12.84% | 670.14% | 784.92% | 784.92% | 784.92% | 784.92% | 784.92% |
| Azenta AZTA | 1.33B Small-cap | -10.24% | -13.37% | 4.76% | -38.90% | -41.99% | -47.46% | -53.90% | -47.09% |
Ownership & Short Interest
Insider Ownership
3.24%
Institutional Ownership
101.86%
Shares Short
2M
Short Ratio
3.74
Short % of Shares Outstanding
3.16%
Average 10-Day Volume
994K
Average 90-Day Volume
606K
AtriCure Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in AtriCure would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ATRC's 52-week high and low?
- In the last 52 weeks, AtriCure reached a high of $43.11 (on January 29, 2025) and a low of $20.20 (on August 8, 2024).
- What is the market cap and P/E ratio for ATRC?
- Curious about AtriCure's size and valuation? Its market capitalization stands at 1.82B. When it comes to valuation, the P/E ratio (trailing twelve months) is -37.85, and the forward P/E (looking ahead) is -57.97.
- Does ATRC pay dividends? If so, what's the yield?
- As for dividends, AtriCure isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are AtriCure's main competitors or similar companies to consider before investing?
When looking at AtriCure, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Intuitive Surgical
ISRG169.94B Healthcare Medical Instruments & Supplies 1.43% 97.21% Becton, Dickinson
BDX53.31B Healthcare Medical Instruments & Supplies -17.97% -26.61% Lemaitre Vascular
LMAT2.11B Healthcare Medical Instruments & Supplies 10.17% 68.46% Anbio Biotechnology
NNNN1.87B Healthcare Medical Instruments & Supplies 784.92% 784.92% Azenta
AZTA1.33B Healthcare Medical Instruments & Supplies -47.46% -53.90% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for AtriCure Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of AtriCure's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -7.85%, the Debt to Equity ratio from the most recent quarter is 16.63, and its Gross Profit Margin stands at 74.54%.
- What is the recent revenue and earnings growth for ATRC?
- Looking at AtriCure's growth, its revenue over the trailing twelve months (TTM) was $500M. Compared to the same quarter last year (YoY), quarterly revenue grew by 17.10%, and quarterly earnings saw a YoY growth of 17.09%.
- How much of ATRC stock is held by insiders and institutions?
- Wondering who owns AtriCure stock? Company insiders (like executives and directors) hold about 3.24% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 101.86%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.